Ovarian cancer: In search of better marker systems based on DNA repair defects

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 640-673

  Varga, Dominic ^a   Deniz, Miriam ^a   Schwentner, Lukas ^a   Wiesmüller, Lisa ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

DNA repair errors; Early detection; Functional biomarker; Ovarian cancer risk; Prediction of therapeutic responsiveness

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; INIPARIB; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN BINDING; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CPG ISLAND; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EPIGENETICS; FAMILIAL CANCER; FANCONI ANEMIA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; HETEROZYGOSITY; HUMAN; MICRONUCLEUS; MICRONUCLEUS TEST; MISMATCH REPAIR; NONHUMAN; ONCOGENE K RAS; ONCOGENE NEU; OVARY CANCER; OVARY CARCINOMA; PATHOPHYSIOLOGY; PROTEOMICS; REVIEW; TUMOR SUPPRESSOR GENE; BIOLOGICAL MODEL; FEMALE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; OVARIAN NEOPLASMS;

BIOMARKERS, TUMOR; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA REPAIR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, GENETIC; OVARIAN NEOPLASMS; PROTEIN BINDING;

EID: 84872178016     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14010640     Document Type: Review

References (171)

1. Hunn, J.; Rodriguez, G.C. Ovarian cancer: Etiology, risk factors, and epidemiology. Clin. Obstet. Gynecol. 2012, 55, 3-23.
2. Altekruse, S.F.; Kosary, C.L.; Krapcho, M.; Neuman, N.; Aminou, R.; Waldron, W.; Ruhl, J.; Howlader, N.; Tatalovich, Z.; Cho, H.; et al. SEER Cancer Statistics Review, 1975-2009. Available online: http://seer.cancer.gov/csr/1975_2007/(accessed on 17 July 2012).
3. Stratton, J.F.; Pharoah, P.; Smith, S.K.; Easton, D.; Ponder, B.A. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br. J. Obstet. Gynaecol. 1998, 105, 493-499.
4. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.; et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266, 66-71.
5. Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; Collins, N.; Gregory, S.; Gumbs, C.; Micklem, G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378, 789-792.
6. Meindl, A.; Hellebrand, H.; Wiek, C.; Erven, V.; Wappenschmidt, B.; Niederacher, D.; Freund, M.; Lichtner, P.; Hartmann, L.; Schaal, H.; et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 2010, 42, 410-414.
7. Loveday, C.; Turnbull, C.; Ruark, E.; Xicola, R.M.; Ramsay, E.; Hughes, D.; Warren-Perry, M.; Snape, K. Breast Cancer Susceptibility Collaboration (UK); Eccles, D.; et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat. Genet. 2012, 44, 475-476.
8. Antoniou, A.; Pharoah, P.D.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, A.; et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72, 1117-1130.
9. Risch, H.A.; McLaughlin, J.R.; Cole, D.E.; Rosen, B.; Bradley, L.; Fan, I.; Tang, J.; Li, S.; Zhang, S.; Shaw, P.A.; et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 2006, 98, 1694-706.
10. Chen, S.; Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007, 25, 1329-1233.
11. Loveday, C.; Turnbull, C.; Ramsay, E.; Hughes, D.; Ruark, E.; Frankum, J.R.; Bowden, G.; Kalmyrzaev, B.; Warren-Perry, M.; Snape, K.; et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat. Genet. 2011, 43, 879-882.
12. Lynch, H.T.; Casey, M.J.; Snyder, C.L.; Bewtra, C.; Lynch, J.F.; Butts, M.; Godwin, A.K. Hereditary ovarian cancer: Molecular genetics, pathology, management, and heterogeneity. Mol. Oncol. 2009, 3, 97-137.
13. Pennington, K.P.; Swisher, E.M. Hereditary ovarian cancer: Beyond he usual suspects. Gynecol. Oncol. 2012, 124, 347-353.
14. Sourbier, C. Ovarian cancer: Emerging molecular-targeted therapies. Biologics 2012, 6, 147-154.
15. Slomski, A. Screening women for ovarian cancer still does more harm than good. JAMA 2012, 307, 2474-2475.
16. Longuespee, R.; Boyon, C.; Desmons, A.; Vinatier, D.; Leblanc, E.; Farre, I.; Wisztorski, M.; Ly, K.; D'Anjou, F.; Day, R.; et al. Ovarian cancer molecular pathology. Cancer Metastasis Rev. 2012, 31, 713-732.
17. Valentini, A.L.; Gui, B.; Miccò, M.; Mingote, M.C.; De Gaetano, A.M.; Ninivaggi, V.; Bonomo, L. Benign and suspicious ovarian masses-MR imaging criteria for characterization: Pictorial review. J. Oncol. 2012, 2012, 481806.
18. Rigakos, G.; Razis, E. BRCAness: Finding the achilles heel in ovarian cancer. Oncologist 2012, 17, 956-962.
19. Claus, E.B.; Schwartz, P.E. Familial ovarian cancer. Update and clinical applications. Cancer 1995, 76, 1998-2003.
20. Cass, I.; Baldwin, R.L.; Varkey, T.; Moslehi, R.; Narod, S.A.; Karlan, B.Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97, 2187-2195.
21. Alsop, K.; Fereday, S.; Meldrum, C.; deFazio, A.; Emmanuel, C.; George, J.; Dobrovic, A.; Birrer, M.J.; Webb, P.M.; Stewart, C.; et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 2012, 30, 2654-2663.
22. Kinzler, K. W; Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997, 386, 761-763.
23. Howlett, N.G.; Taniguchi, T.; Durkin, S.G.; D'Andrea, A.D.; Glover, T.W. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum. Mol. Genet. 2005, 14, 693-701.
24. Kennedy, R.D.; D'Andrea, A.D. The Fanconi anemia/BRCA pathway: New faces in the crowd. Genes Dev. 2005, 19, 2925-2940.
25. Walsh, T.; King, M.C. Ten genes for inherited breast cancer. Cancer Cell 2007, 11, 103-105.
26. Surtees, J.A.; Argueso, J.L.; Alani, E. Mismatch repair proteins: Key regulators of genetic recombination. Cytogenet. Genome Res. 2004, 107, 146-159.
27. Siehler, S.Y.; Schrauder, M.; Gerischer, U.; Cantor, S.; Marra, G.; Wiesmüller, L. Human Mlh1 monitors homologous recombination independently of mismatch repair and damage signaling. DNA Repair 2009, 8, 242-252.
28. Lavin, M.F. Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat. Rev. Mol. Cell Biol. 2008, 9, 759-769.
29. Gatz, S.A.; Wiesmüller, L. p53 in recombination and repair. Cell Death Differ. 2006, 13, 1003-1006.
30. Thompson, L.H.; Hinz, J.M. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: Mechanistic insights. Mutat. Res. 2009, 668, 54-72.
31. O'Brien, V.; Brown, R. Signalling cell cycle arrest and cell death through the MMR system. Carcinogenesis 2006, 27, 682-692.
32. Ewald, B.; Sampath, D.; Plunkett, W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res. 2008, 68, 7947-7955.
33. Sato, K.; Ohta, T.; Venkitaraman, A.R. A mitotic role for the DNA damage-responsive CHK2 kinase. Nat. Cell Biol. 2010, 12, 424-425.
34. Hombauer, H.; Srivatsan, A.; Putnam, C.D.; Kolodner, R.D. Mismatch repair, but not heteroduplex rejection, is temporally coupled to DNA replication. Science 2011, 334, 1713-1716.
35. Schlacher, K.; Wu, H.; Jasin, M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 2012, 22, 106-116.
36. Mukhopadhyay, A.; Elattar, A.; Cerbinskaite, A.; Wilkinson, S.J.; Drew, Y.; Kyle S.; Los, G.; Hostomsky, Z.; Edmondson, R.J.; Curtin, N.J. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 2010, 16, 2344-2351.
37. Rothfuss, A.; Schütz, P.; Bochum, S.; Volm, T.; Eberhardt, E.; Kreienberg, R.; Vogel, W.; Speit, G. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res. 2000, 60, 390-394.
38. Redon, C.E.; Nakamura, A.J.; Zhang, Y.W.; Ji, J.J.; Bonner, W.M.; Kinders, R.J.; Parchment, R.E.; Doroshow, J.H.; Pommier, Y. Histone γH2AX and Poly(ADP-Ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res. 2010, 16, 4532-4542.
39. Keimling, M.; Deniz, M.; Varga, D.; Stahl, A.; Schrezenmeier, H.; Kreienberg, R.; Hoffmann, I.; König, J.; Wiesmüller, L. The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility. FASEB J. 2012, 26, 2094-2104.
40. Roy, R.; Chun, J.; Powell, S.N. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer 2011, 12, 68-78.
41. Somyajit, K.; Subramanya, S.; Nagaraju, G. RAD51C: A novel cancer susceptibility gene is linked to FANconi anemia and breast cancer. Carcinogenesis 2010, 12, 2031-2038.
42. Bozzao, C.; Lastella, P.; Stella, A. Anticipation in lynch syndrome: Where we are where we go. Curr. Genomics 2011, 12, 451-465.
43. Thorstenson, Y.R.; Roxas, A.; Kroiss, R.; Jenkins, M.A.; Yu, K.M.; Bachrich, T.; Muhr, D.; Wayne, T.L.; Chu, G.; Davis, R.W.; et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 2003, 63, 3325-3333.
44. Roemer, K. Mutant p53: Gain-of-function oncoproteins and wild-type p53 inactivators. Biol. Chem. 1999, 380, 879-887.
45. Malkin, D. Li-Fraumeni syndrome. Genes Cancer 2011, 2, 475-484.
46. McCuaig, J.M.; Armel, S.R.; Novokmet, A.; Ginsburg, O.M.; Demsky, R.; Narod, S.A.; Malkin, D. Routine TP53 testing for breast cancer under age 30: Ready for prime time? Fam. Cancer 2012, 11, 607-613.
47. Bertrand, P.; Saintigny, Y.; Lopez, B.S. p53's double life: Transactivation-independent repression of homologous recombination. Trends Genet. 2004, 20, 235-243.
48. Shen, W.H.; Balajee, A.S.; Wang, J.; Wu, H.; Eng, C.; Pandolfi, P.P.; Yin, Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128, 157-170.
49. Jin, S.; Mao, H.; Schnepp, R.W.; Sykes, S.M.; Silva, A.C.; D'Andrea, A.D.; Hua, X. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 2003, 63, 4204-4210.
50. Marek, L.R.; Kottemann, M.C.; Glazer, P.M.; Bale, A.E. MEN1 and FANCD2 mediate distinct mechanisms of DNA crosslink repair. DNA Repair 2008, 7, 476-486.
51. Gallo, A.; Agnese, S.; Esposito, I.; Galgani, M.; Avvedimento, V.E. Menin stimulates homology-directed DNA repair. FEBS Lett. 2010, 584, 4531-4536.
52. Lindor, N.M.; McMaster, M.L.; Lindor, C.J.; Greene, M.H. Concise handbook of familial cancer susceptibility syndromes-second edition. J. Natl. Cancer Inst. Monogr. 2008, 38, 1-93.
53. Hoeijmakers, J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411, 366-374.
54. Jackson, S.P.; Bartek, J. The DNA-damage response in human biology and disease. Nature 2009, 461, 1071-1078.
55. Schrauder, M.; Wiesmüller, L. DNA Repair. In Apoptosis and Cancer Therapy, 1st ed.; Debatin, K.M., Fulda, S., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2006; Volume 2, pp. 822-846.
56. Caldecott, K.W. Single-strand break repair and genetic disease. Nat. Rev. Genet. 2008 9, 619-631.
57. Liu, Y.; Kadyrov, F.A.; Modrich, P. PARP-1 enhances the mismatch-dependence of 5'-directed excision in human mismatch repair in vitro. DNA Repair 2011, 10, 1145-1153.
58. Huertas, P. DNA resection in eukaryotes: Deciding how to fix the break. Nat. Struct. Mol. Biol. 2010, 17, 11-16.
59. Weterings, E.; Chen, D.J. The endless tale of non-homologous end-joining. Cell Res. 2008, 18, 114-124.
60. O'Donovan, P.J.; Livingston, D.M. BRCA1 and BRCA2: Breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010, 31, 961-967.
61. Nussenzweig, A.; Nussenzweig, M.C. A backup DNA repair pathway moves to the forefront. Cell 2007, 131, 223-225.
62. Bryant, H.E.; Petermann, E.; Schultz, N.; Jemth, A.S.; Loseva, O.; Issaeva, N.; Johansson, F.; Fernandez, S.; McGlynn, P.; Helleday, T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009, 28, 2601-2615.
63. Malpica, A.; Deavers, M.T.; Lu, K.; Bodurka, D.C.; Atkinson, E.N.; Gershenson, D.M.; Silva, E.G. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 2004, 28, 496-504.
64. Shih, I.; Kurman, R.J. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004, 164, 1511-1518.
65. Cho, K.R.; Shih, I. Ovarian cancer. Annu. Rev. Pathol. 2009, 4, 287-313.
66. Merritt, M.A.; Cramer, D.W. Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomarkers 2010, 9, 287-305.
67. Kaku, T.; Ogawa, S.; Kawano, Y.; Ohishi, Y.; Kobayashi, H.; Hirakawa, T.; Nakano, H. Histological classification of ovarian cancer. Med. Electron. Microsc. 2003, 36, 9-17.
68. Cai, K.Q.; Albarracin, C.; Rosen, D.; Zhong, R.; Zheng, W.; Luthra, R.; Broaddus, R.; Liu, J. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum. Pathol. 2004, 35, 552-559.
69. Naik, J.D.; Seligmann, J.; Perren, T.J. Mucinous tumours of the ovary. J. Clin. Pathol. 2012, 65, 580-584.
70. Wamunyokoli, F.W.; Bonome, T.; Lee, J.Y.; Feltimate, C.M.; Welch, W.R.; Radonovich, M.; Pise-Masison, C.; Brady, J.; Hao, K.; Berkowitz, R.S.; et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin. Cancer Res. 2006, 12, 690-700.
71. Koh, S.C.; Razvi, K.; Chan, Y.H.; Narasimhan, K.; Ilancheran, A.; Low, J.J.; Choolani, M.; Ovarian Cancer Research Consortium of SE Asia. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch. Gynecol. Obstet. 2011, 284, 183-190.
72. Meden, H.; Fattahi-Meibodi, A. CA 125 in benign gynecological conditions. Int. J. Biol. Markers 1998, 13, 231-237.
73. Kim, J. H; Skates, S.J.; Uede, T.; Wong, K.K.; Schorge, J.O.; Feltmate, C.M.; Berkowitz, R.S.; Cramer, D.W.; Mok, S.C. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287, 1671-1679.
74. Diamandis, E.P.; Scorilas, A.; Fracchioli, S.; van Gramberen, M.; de Bruijn, H.; Henrik, A.; Soosaipillai, A.; Grass, L.; Yousef, G.M.; Stenman, U.H.; et al. Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 2003, 21, 1035-1043.
75. Kishi, T.; Grass, L.; Soosaipillai, A.; Scorilas, A.; Harbeck, N.; Schmalfeldt, B.; Dorn, J.; Mysliwiec, M.; Schmitt, M.; Diamandis, E.P. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003, 63, 2771-2774.
76. Matsuzaki, H.; Kobayashi, H.; Yagyu, T.; Wakahara, K.; Kondo, T.; Kurita, N.; Sekino, H.; Inagaki, K.; Suzuki, M.; Kanayama, N.; et al. Plasma bikunin as a favorable prognostic factor in ovarian cancer. J. Clin. Oncol. 2005, 23, 1463-1472.
77. Nowee, M.E.; Snijders, A.M.; Rockx, D.A.; de Wit, R.M.; Kosma, V.M.; Hämäläinen, K.; Schouten, J.P.; Verheijen, R.H.; van Diest, P.J.; Albertson, D.G.; et al. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J. Pathol. 2007, 213, 46-55.
78. Bandiera, E.; Franceschini, R.; Specchia, C.; Bignotti, E.; Trevisiol, C.; Gion, M.; Pecorelli, S; Santin, A.D.; Ravaggi, A. Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet. Gynecol. 2012, 2012, 245756.
79. Moore, R.G.; Brown, A.K.; Miller, M.C.; Skates, S.; Allard, W.J.; Verch, T.; Steinhoff, M.; Messerlian, G.; DiSilvestro, P.; Granai, C.O.; et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 2008, 108, 402-408.
80. Yurkovetsky, Z.; Skates, S.; Lomakin, A.; Nolen, B.; Pulsipher, T.; Modugno, F.; Marks, J.; Godwin, A.; Gorelik, E.; Jacobs, I.; et al. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 2010, 28, 2159-2166.
81. Chan, K.K.; Chen, C.A.; Nam, J.H.; Ochiai, K.; Wilailak, S.; Choon, A.T.; Sabaratnam, S.; Hebbar, S., Sickan, J.; Schodin, B.A.; et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol. Oncol. 2012, doi:10.1016/j.ygyno.2012.09.034.
82. Escudero J.M.; Auge, J.M.; Filella, X.; Torne, A.; Pahisa, J.; Molina, R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin. Chem. 2011, 57, 1534-1544.
83. Freydanck, M.K.; Laubender, R.P., Rack, B.; Schumacher, L.; Jeschke, U.; Scholz, C. Two-marker combinations for preoperative discrimination of benign and malignant ovarian masses. Anticancer Res. 2012, 32, 2003-2008.
84. Van Gorp, T.; Cadron, I.; Despierre, E.; Daemen, E.; Daemen, A.; Leunen, K.; Amant, F.; Timmermann, D.; de Moor, B.; Vergote, I. HE4 and CA125 as a diagnostic test in ovarian cancer: Prospective validation oft he risk of ovarian malignancy algorithm. Br. J. Cancer 2011, 104, 863-870.
85. Van Gorp, T.; Veldman, J.; van Calster, B.; Cadron, I.; Leunen, K.; Amant, F.; Timmermann, D.; Vergote, I. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur. J. Cancer 2012, 48, 1649-1656.
86. Li, F.; Tie, R.; Chang, K.; Wang, F.; Deng, S.; Lu, W.; Yu, L.; Chen, M. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer. A meta-analysis. BMC Cancer 2012, 19, 258.
87. Trudel, D.; Tetu, B.; Gregoire, J.; Plante, M.; Renaud, M.C.; Bachvarov, D.; Douville, P.; Bairate, I. Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol. Oncol. 2012, doi:10.1016/j.ygyno.2012.09.003.
88. Kong, S.Y.; Han, M.H.; Yoo, H.J.; Hwang, J.H.; Lim, M.C.; Seo, S.S.; Yoo, C.W.; Kim, J.H.; Park, S.Y.; Kang, S. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann. Surg. Oncol. 2012, 19, 1707-1712.
89. Georgakopoulos, P.; Mehmood, S.; Akalin, A.; Shroyer, K.R. Immunohistochemical localization of HE4 in benign, borderline, and malignant lesions of the ovary. Int. J. Gynecol. Pathol. 2012, 31, 517-523.
90. Novotny, Z.; Presl, J.; Kucera, R.; Topolcan, O.; Vrzalova, J.; Fuchsova, R.; Betincova, L.; Rokyta, Z. HE4 and ROMA index in Czech postmenopausal women. Anticancer Res. 2012, 32, 4137-4140.
91. Urban, N.; Thorpe, J.; Karlan, B.Y.; McIntosh, M.W.; Palomares, M.R.; Daly, M.B.; Paley, P.; Drescher, C.W. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2012, 21, 2087-2094.
92. Suh, K.S.; Park S.W.; Castro, A.; Patel, H.; Blake, M.L.; Goy, A. Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev. Mol. Diagn. 2010, 10, 1069-1083.
93. Zhang, B.; Barekati, Z.; Kohler, C.; Radpour, R.; Asadollahi, R.; Holzgreve, W.; Zhong, X.Y. Proteomics and biomarkers for ovarian cancer diagnosis. Ann. Clin. Lab. Sci. 2010, 40, 218-225.
94. Nolen, B.M.; Lokshin, A.E. Protein biomarkers of ovarian cancer: The forest and the trees. Future Oncol. 2012, 8, 55-74.
95. Le Page, C.; Huntsman, D.G.; Provencher, D.M.; Mes-Masson, A.-M. Predictive and prognostic protein biomarkers in epithelial ovarian cancer: Recommendation for future studies. Cancers 2010, 2, 913-954.
96. Visintin, I.; Feng, Z.; Longton, G.; Ward, D.C.; Alvero, A.B.; Lai, Y.; Tenthorey, J.; Leiser, A.; Flores-Saaib, R.; Yu, H.; et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 2008, 14, 1065-1072.
97. Mcintosh, M.; Anderson, G.; Drescher, C.; Hanash, S.; Urban, N.; Brown, P.; Gambhir, S.S.; Coukos, G.; Laird, P.W.; Nelson, B.; et al. Ovarian cancer early detection claims are biased. Clin. Cancer Res. 2008, 14, 7574.
98. Zhang, Z.; Bast, R.C., Jr.; Yu, Y.; Li, J.; Sokoll, L.J.; Rai, A.J.; Rosenzweig, J.M.; Cameron, B.; Wang, Y.Y.; Meng, X.Y.; et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
99. Skates, S.J.; Horick, N.; Yu, Y.; Xu, F.J.; Berchuck, A.; Havrilesky, L.J.; de Bruijn, H.W.; van der Zee, A.G.; Woolas, R.P.; Jacobs, I.J.; et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 2004, 22, 4059-4066.
100. Amonkar, S.D.; Bertenshaw, G.P.; Chen, T.H.; Bergstrom, K.J.; Zhao, J.; Seshaiah, P.; Yip, P.; Mansfield, B.C. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 2009, 4, e4599.
101. Feuk, L.; Carson, A.R.; Scherer, S.W. Structural variation in the human genome. Nat. Rev. Genet. 2006, 7, 85-97.
102. Alkan, C.; Bradley, P.C.; Eichler, E. Genome structural variation discovery and genotyping. Nat. Rev. 2011, 12, 363-376.
103. Stankiewicz, P.; Lupski, J.R. Structural variation in the human genome and its role in disease. Annu. Rev. Med. 2010, 61, 437-455.
104. Stranger, B.E.; Forrest, M.S.; Dunning, M.; Ingle, C.E.; Beazley, C.; Thorne, N.; Redon, R.; Bird, C.P.; de Grassi, A.; Lee, C.; et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007, 315, 848-853.
105. Albertson, D.G.; Collins, C.; McCormick, F.; Gray, J.W. Chromosome aberrations in solid tumors. Nat. Genet. 2003, 34, 369-376.
106. Kalb, R.; Neveling, K.; Nanda, I.; Schindler, D.; Hoehn, H. Fanconi Anemia: Causes and Consequences of Genetic Instability. In Genome and Disease. Genome Dyn; Volff, J.N., Ed.; Karger: Basel, Switzerland, 2006; Volume 1, pp. 218-242.
107. Negrini, S.; Gorgoulis, V.G.; Halazonetis, T.D. Genomic instability-An evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 2010, 11, 220-228.
108. Engert, S.; Wappenschmidt, B.; Betz, B.; Kast, K.; Kutsche, M.; Hellebrand, H.; Goecke, T.O.; Kiechle, M.; Niederacher, D.; Schmutzler, R.K.; et al. MLPA screening in the BRCA1 gene from 1506 German hereditary breast cancer cases: Novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases. Hum. Mutat. 2008, 29, 948-958.
109. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615.
110. Hilton, J.L.; Geisler, J.P.; Rathe, J.A.; Hattermann-Zogg, M.A.; DeYoung, B.; Buller, R.E. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl. Cancer Inst. 2002, 94, 1396-1406.
111. Nakayama, K.; Nakayama, N.; Kurman, R.J.; Cope, L.; Pohl, G.; Samuels, Y.; Velculescu, V.E.; Wang, T.L.; Shih, I.M. Sequence mutations and amplifications of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther. 2006, 5, 779-785.
112. Engler, D.A.; Gupta, S.; Growdon, W.B.; Drapkin, R.I.; Nitta, M.; Sergent, P.A.; Allred, S.F.; Gross, J.; Deavers, M.T.; Kuo, W.L.; et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One 2012, 7, e30996.
113. Gorringe, K.L.; George, J.; Anglesio, M.S.; Ramakrishna, M.; Etemadmoghadam, D.; Cowin, P.; Sridhar, A.; Williams, L.H.; Boyle, S.E.; Yanaihara, N.; et al. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One 2010, 5, e11408.
114. Schwartz, D.R.; Kardia, S.L.; Shedden, K.A.; Kuick, R.; Michailidis, G.; Taylor, J.M.; Misek, D.E.; Wu, R.; Zhai, Y.; Darrah, D.M.; et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002, 62, 4722-4729.
115. Bonome, T.; Lee, J.Y.; Park, D.C.; Radonovich, M.; Pise-Masison, C.; Brady, J.; Gardner, G.J.; Hao, K.; Wong, W.H.; Barrett, J.C.; et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary Cancer Res. 2005, 65, 10602-10612.
116. Tothill, R.W.; Tinker, A.V.; George, J.; Brown, R.; Fox, S.B.; Lade, S.; Johnson, D.S.; Trivett, M.K.; Etemadmoghadam, D.; Locandro, B.; et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 2008, 14, 5198-5208.
117. Jazaeri, A.A.; Awtrey, C.S.; Chandramouli, G.V.; Chuang, Y.E.; Khan, J.; Sotiriou, C.; Aprelikova, O.; Yee, C.J.; Zorn, K.K.; Birrer, M.J.; et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin. Cancer Res. 2005, 11, 6300-6310.
118. Fekete, T.; Rásó, E.; Pete, I.; Tegze, B.; Liko, I.; Munkácsy, G.; Sipos, N.; Rigó, J., Jr.; Györffy, B. Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Int. J. Cancer 2012, 131, 95-105.
119. Kang, J.; D'Andrea, A.D.; Kozono, D. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J. Natl. Cancer Inst. 2012, 104, 670-681.
120. Zeller, C.; Dai, W.; Steele, N.L.; Siddiq, A.; Walley, A.J.; Wilhelm-Benartzi, C.S.; Rizzo, S.; van der Zee, A.; Plumb, J.A.; Brown, R. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012, 31, 4567-4576.
121. Balch, C.; Matei, D.E.; Huang, T.H.; Nephew, K.P. Role of epigenomics in ovarian and endometrial cancers. Epigenomics 2010, 2, 419-447.
122. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128, 683-692.
123. Baldwin, R.L.; Nemeth, E.; Tran, H.; Shvartsman, H.; Cass, I.; Narod, S.; Karlan, B.Y. BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res. 2000, 60, 5329-5333.
124. Strathdee, G.; Appleton, K.; Illand, M.; Millan, D.W.; Sargent, J.; Paul, J.; Brown, R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 2001, 158, 1121-1127.
125. Rathi, A.; Virmani, A.K.; Schorge, J.O.; Elias, K.J.; Maruyama, R.; Minna, J.D.; Mok, S.C.; Girard, L.; Fishman, D.A.; Gazdar, A.F. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin. Cancer Res. 2002, 8, 3324-3331.
126. Teodoridis, J.M.; Hall, J.; Marsh, S.; Kannall, H.D.; Smyth, C.; Curto, J.; Siddiqui, N.; Gabra, H.; McLeod, H.L.; Strathdee, G.; et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 2005, 65, 8961-8967.
127. De Caceres, I.; Battagli, C.; Esteller, M.; Herman, J.G.; Dulaimi, E.; Edelson, M.I.; Bergman, C.; Ehya, H.; Eisenberg, B.L.; Cairns, P. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004, 64, 6476-6481.
128. Wiley, A.; Katsaros, D.; Chen, H.; Rigault de la Longrais, I.A.; Beeghly, A.; Puopolo, M.; Singal, R.; Zhang, Y.; Amoako, A.; Zelterman, D.; et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006, 107, 299-308.
129. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of "BRCAness" in sporadic cancers. Nat. Rev. Cancer 2004, 4, 814-819.
130. Maradeo, M.E.; Cairns, P. Translational application of epigenetic alterations: Ovarian cancer as a model. FEBS Lett. 2011, 585, 2112-2120.
131. Stefansson, O.A.; Villanueva, A.; Vidal, A.; Martí, L.; Esteller, M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 2012, 7, 1225-1229.
132. Ralhan, R.; Kaur, J.; Kreienberg, R.; Wiesmüller, L. Links between DNA double strand break repair and breast cancer: Accumulating evidence from both familial and nonfamilial cases. Cancer Lett. 2007, 248, 1-17.
133. Litman, R.; Peng, M.; Jin, Z.; Zhang, F.; Zhang, J.; Powell, S.; Andreassen, P.R.; Cantor, S.B. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005, 8, 255-265.
134. Fenech, M.; Morley, A.A. Kinetochore detection in micronuclei: An alternative method for measuring chromosome loss. Mutagenesis 1989, 4, 98-104.
135. Fenech, M. The in vitro micronucleus technique. Mutat. Res. 2000, 455, 81-95.
136. Zunino, A.; Degan, P.; Vigo, T.; Abbondandolo, A. Hydrogen peroxide: Effects on DNA, chromosomes, cell cycle and apoptosis induction in Fanconi's anemia cell lines. Mutagenesis 2001, 16, 283-288.
137. Gutiérrez-Enríquez, S.; Hall, J. Use of the cytokinesis-block micronucleus assay to measure radiation-induced chromosome damage in lymphoblastoid cell lines. Mutat. Res. 2003, 535, 1-13.
138. Baeyens, A.; Thierens, H.; Claes, K.; Poppe, B.; de Ridder, L.; Vral, A. Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. Int. J. Radiat. Biol. 2004, 80, 745-756.
139. Cardinale, F.; Bruzzi, P.; Bolognesi, C. Role of micronucleus test in predicting breast cancer susceptibility: A systematic review and meta-analysis. Br. J. Cancer 2012, 106, 780-790.
140. Akyüz, N.; Boehden, G.S.; Süsse, S.; Rimek, A.; Preuss, U.; Scheidtmann, K.H.; Wiesmüller, L. DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol. Cell Biol. 2002, 22, 6306-6317.
141. Keimling, M.; Kaur, J.; Bagadi, S.A.; Kreienberg, R.; Wiesmüller, L.; Ralhan, R. A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens. Int. J. Cancer 2008, 123, 730-736.
142. Keimling, M.; Volcic, M.; Csernok, A.; Wieland, B.; Dörk, T.; Wiesmüller, L. Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways. FASEB J. 2011, 25, 3849-3860.
143. Ashworth, A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 2008, 26, 3785-3790.
144. Romero, I.; Bast, R.C., Jr. Minireview: Human ovarian cancer: Biology, current management, and paths to personalizing therapy. Endocrinology 2012, 153, 1593-1602.
145. Heintz, A.P.; Odicino, F.; Maisonneuve, P.; Quinn, M.A.; Benedet, J.L.; Creasman, W.T.; Ngan, H.Y.; Pecorelli, S.; Beller, U. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int. J Gynaecol. Obstet. 2006, 95, S161-S192.
146. Bristow, R.E.; Tomacruz, R.S.; Armstrong, D.K.; Trimble, E.L.; Montz, FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during paltinum era: A-meta analysis. J. Clin. Oncol. 2002, 20, 1248-1259.
147. Kommoss, S.; Rochon, J.; Harter, P.; Heitz, F.; Grabowski, J.P.; Ewald-Riegler, N.; Haberstroh, M.; Neunhoeffer, T.; Barinoff, J.; Gomez, R.; et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann. Surg. Oncol. 2010, 17, 279-286.
148. Harter, P.; du Bois, A. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr. Opin. Oncol. 2005, 17, 505-514.
149. Rose, P.G.; Nerenstone, S.; Brady, M.F.; Clarke-Pearson, D.; Olt, G.; Rubin, S.C.; Moore, D.H.; Small, J.M.; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Eng. J. Med. 2004, 351, 2489-2497.
150. Du Bois, A.; Marth, C.; Pfisterer, J.; Harter, P.; Hilpert, F.; Zeimet, A.G.; Sehouli, J. Neoadjuvant chemotherapy cannot be regarded as adequat routine therapy strategy of advanced ovarian cancer. Int. J. Gynaecol. Cancer 2012, 22, 182-185.
151. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002, 360, 505-515.
152. Du Bois, A.; Lück, H.J.; Meier, W.; Adams, H.P.; Möbus, V.; Costa, S.; Bauknecht, T.; Richter, B.; Warm, M.; Schröder, W.; et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003, 95, 1320-1329.
153. Du Bois, A.; Pfisterer, J.; Burchardi, N.; Loibl, S.; Huober, J.; Wimberger, P.; Burges, A.; Stähle, A.; Jackisch, C.; Kölbl, H.; et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol. Oncol. 2007, 107, 518-525.
154. Du Bois, A.; Herrstedt, J.; Hardy-Bessard, A.C.; Müller, H.H.; Harter, P.; Kristensen, G.; Joly, F.; Huober, J.; Avall-Lundqvist, E.; Weber, B.; et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J. Clin. Oncol. 2010, 28, 4162-4169.
155. Fujiwara, K.; Aotani, E.; Hamano, T.; Nagao, S.; Yoshikawa, H.; Sugiyama, T.; Kigawa, J.; Aoki, D.; Katsumata, N.; Takeuchi, M.; et al. A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Jpn. J. Clin. Oncol. 2011, 41, 278-282.
156. Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C.; et al. ICON7 Investigators. A phase 3 trials of bevacicumab in ovarian cancer. N. Engl. J. Med. 2011, 365, 2484-2496.
157. Tan, D.S.; Rothermundt, C.; Thomas, K.; Bancroft, E.; Eeles, R.; Shanley, S.; Ardern-Jones, A.; Norman, A.; Kaye, S.B.; Gore, M.E. "BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 2008, 26, 5530-5536.
158. Huehls, A.M.; Wagner, J.M.; Huntoon, C.J.; Karnitz, L.M. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a PARP inhibitor in a novel drug combination. Mol. Pharmacol. 2012, 82, 767-776.
159. Mégnin-Chanet, F.; Bollet, M.A.; Hall, J. Targeting poly(ADP-ribose)polymerase activity for cancer therapy. Cell Mol. Life Sci. 2010, 67, 3649-3662.
160. Weil, M.K.; Chen, A.P. PARP inhibitor treatment in ovarian and breast cancer. Curr. Probl. Cancer 2012, 35, 7-50.
161. Bryant, H.E.; Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434, 913-917.
162. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917-921.
163. Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M.J.; et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361, 123-134.
164. Annunziata, C.M.; Shaughnessy, J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin. Cancer Res. 2010, 16, 4517-4526.
165. Chionh, F.; Mitchell, G.; Lindeman, G.J.; Friedlander, M.; Scott, C.L. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions. Asia Pac. J. Clin. Oncol. 2011, 7, 197-211.
166. Patel, A.G.; De Lorenzo, S.B.; Flatten, K.S.; Poirier, G.G.; Kaufmann, S.H. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin. Cancer Res. 2012, 18, 1655-1662.
167. Liu, X.; Shi, Y.; Maag, D.X.; Palma, J.P.; Patterson, M.J.; Ellis, P.A.; Surber, B.W.; Ready, D.B.; Soni, N.B.; Ladror, U.S.; et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a Bona Fide PARP inhibitor. Clin. Cancer Res. 2012, 18, 510-523.
168. Fong, P.C.; Yap, T.A.; Boss, D.S.; Carden, C.P.; Mergui-Roelvink, M.; Gourley, C.; De Greve, J.; Lubinski, J.; Shanley, S.; Messiou, C.; et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 2010, 28, 2512-2519.
169. Wang, Z.C.; Birkbak, N.J.; Culhane, A.C.; Drapkin, R.; Fatima, A.; Tian, R.; Schwede, M.; Alsop, K.; Daniels, K.E.; Piao, H.; et al. Profiles of genomic instability in hgh-grade serous ovarian cancer predict treatment outcome. Clin. Cancer Res. 2012, 18, 5806-5815.
170. Mukhopadhyay, A.; Plummer, E.R.; Elattar, A.; Soohoo, S.; Uzir, B.; Quinn, J.E.; McCluggaga, W.G.; Maxwell, P.; Aneke, H.; Curtin, N.J.; et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum, and survival. Cancer Res. 2012, 15, 5675-5682.
171. Nishikawa, H.; Wu, W.; Koike, A.; Kojima, R.; Gomi, H.; Fukuda, M.; Ohta, T. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 2009, 69, 111-119.